Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2495 EUR 2.25% Market Closed
Market Cap: 31.1m EUR
SIGHT
/
Cash Flow Statement
/
Change in Working Capital

Gensight Biologics SA
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Change in Working Capital
€1.2m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Change in Working Capital
-€89.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Change in Working Capital
€13m
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Change in Working Capital
-€66m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
-116%
Inventiva SA
PAR:IVA
Change in Working Capital
€11.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Change in Working Capital
€2.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Gensight Biologics SA
Glance View

Market Cap
31.1m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.2383 EUR
Overvaluation 4%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Gensight Biologics SA's Change in Working Capital?
Change in Working Capital
1.2m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Change in Working Capital amounts to 1.2m EUR.

What is Gensight Biologics SA's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-4%

Over the last year, the Change in Working Capital growth was 209%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 238,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.